Arovella Therapeutics (ALA) Investor Presentation summary

Investment highlights and leadership

• Developing off-the-shelf iNKT cell therapies targeting blood and solid cancers, with a proprietary clinic-ready manufacturing process and strategic acquisitions to strengthen the platform.

• Lead product ALA-101 is advancing to phase 1 clinical trials for CD19-positive blood cancers, expected to start in early 2026.

• Leadership and board have extensive experience in drug and cell therapy development.

Financial overview and funding

• Market capitalisation of $107.97 million as of November 2025, with a cash balance of $21.9 million at 30 September 2025.

• Completed a $15 million placement to fund phase 1 trial enrolment and initial data reporting for ALA-101.

• Share price ranged from $0.068 to $0.210 over the past year.

Technology and clinical development

• iNKT cells offer a next-generation platform with strong safety, no GVHD, and multimodal anti-cancer mechanisms, outperforming conventional CAR-T cells in preclinical models.

• ALA-101 demonstrated rapid tumour eradication and increased survival in mice compared to CAR19-T cells, with evidence of persistent activity against relapsed tumours.

• Clinic-ready, semi-automated manufacturing process enables large-scale production and plug-and-play creation of new CAR-iNKT products.